FDA-cleared profile

Trinias

Shimadzu Corporation

Trinias is an interventional fluoroscopic X-ray system for diagnostic and interventional angiography, including cardiac, neurovascular, abdominal, peripheral, rotational, multipurpose, and whole-body radiographic or fluoroscopic procedures.

Evidence status: each field shows source quality, applicability, and review date. Research pending, information not established in reviewed sources, and vendor documentation pending are distinct outcomes.

Clinical fit

What this tool is for

Start with the authorized purpose, then verify how it fits your service line and reading workflow.

Exact purpose
Trinias is an interventional fluoroscopic X-ray system for diagnostic and interventional angiography, including cardiac, neurovascular, abdominal, peripheral, rotational, multipurpose, and whole-body radiographic or fluoroscopic procedures.
FDA source Exact FDA submission Checked 2026-09-04
Intended users
Qualified radiologists, interventional physicians, surgeons, technologists, and other trained fluoroscopy professionals.
FDA source Exact FDA submission Checked 2026-09-04
Care setting and population
Hospital radiography, fluoroscopy, interventional, vascular, cardiac, or procedural departments.
FDA source Exact FDA submission Checked 2026-09-04
Workflow role
Fluoroscopic or radiographic acquisition, visualization, guidance, and release-specific image processing.
FDA source Exact FDA submission Checked 2026-09-04
Required input
X-ray projection data, fluoroscopic sequences, patient positioning, contrast or procedure inputs, and user selections.
FDA source Exact FDA submission Checked 2026-09-04
Output and human action
Radiographic or fluoroscopic images, overlays, measurements, and procedure views for professional review.
FDA source Exact FDA submission Checked 2026-09-04
Limitations
Operator selection, patient positioning, contrast, radiation dose, anatomy, calibration, and procedure-specific conditions affect applicability; treating physicians remain responsible for decisions.
FDA source Exact FDA submission Checked 2026-09-04

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K252099
FDA source Exact FDA submission Checked 2026-08-31
Modality
Fluoroscopy/Angiography
FDA source Exact FDA submission Checked 2026-09-04
Anatomy
Heart, neurovascular, abdominal, peripheral vessels, and whole body
FDA source Exact FDA submission Checked 2026-09-04
Clearance type
510(k)
FDA source Exact FDA submission Checked 2026-08-31
Decision date
2026-03-24
FDA source Exact FDA submission Checked 2026-08-31
FDA status
FDA-cleared
FDA source Exact FDA submission Checked 2026-08-31

Implementation

Questions for IT, informatics, and operations

Use these fields to structure a vendor demo, security review, and implementation estimate.

Integration
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

The public exact-submission material does not establish a complete integration contract. Confirm DICOM, worklist, identity, interfaces, exports, routing, audit behavior, and downtime locally.

Deployment and data flow
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

The public exact-submission material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.

Security and privacy
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-09-04

Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

Training and support
Only qualified radiologists, interventional physicians, surgeons, technologists, and other trained fluoroscopy professionals should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
FDA source Exact FDA submission Checked 2026-09-04
Monitoring and change control
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Operator selection, patient positioning, contrast, radiation dose, anatomy, calibration, and procedure-specific conditions affect applicability; treating physicians remain responsible for decisions.
Public source Product family Checked 2026-09-04

Current vendor material is product-family context for K252099; confirm exact cleared version, enabled options, deployment, and local compatibility.

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K252099 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Exact public integration details remain incomplete; establish and test the supported input, output, identity, routing, archive, and downtime contract locally.

product family · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally. Current vendor material is product-family context; confirm exact release, enabled options, deployment, and local compatibility.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Operator selection, patient positioning, contrast, radiation dose, anatomy, calibration, and procedure-specific conditions affect applicability; treating physicians remain responsible for decisions.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.

Lifecycle monitoring

Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Operator selection, patient positioning, contrast, radiation dose, anatomy, calibration, and procedure-specific conditions affect applicability; treating physicians remain responsible for decisions.

product family · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. Current vendor material is product-family context; confirm exact release, enabled options, deployment, and local compatibility.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version.

Evidence summary
The exact FDA decision material describes the labeled angiographic and radiographic workflows and system verification. The short public decision document does not establish a product-wide clinical sensitivity or specificity claim.
FDA source Exact FDA submission Checked 2026-09-04
Reported sensitivity
Not applicable
Not applicable Not applicable Checked 2026-09-04

Sensitivity is not a product-wide endpoint for this system or software function. Compare only an exact endpoint, threshold, population, version, and source if one is later verified.

Reported specificity
Not applicable
Not applicable Not applicable Checked 2026-09-04

Specificity is not a product-wide endpoint for this system or software function. Compare only an exact endpoint, threshold, population, version, and source if one is later verified.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K252099 FDA evidence package for Trinias

FDA substantial-equivalence decision with system, software, image-quality, safety, EMC, and usability verification · Adult diagnostic and interventional angiography and radiographic or fluoroscopic procedures across the exact labeled anatomy

exact submission · Tested version: K252099 exact FDA configuration · Sponsor or vendor study

K252099

Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Economics and lifecycle

Budget and ongoing governance

These are common procurement questions; unknown values remain visible until a source supports them.

Pricing and total cost
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

Reimbursement and coding
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
Public source Not applicable Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance or approval.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K252099 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
Public source Exact FDA submission Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Buyer worksheet

Open questions to take to the vendor

Open evaluation checklist

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
26Fields reviewed
10Source classes checked
0Unreviewed PubMed leads
0Unreviewed trial leads
0Unreviewed FDA recall leads

This submission was added after the prior exact-submission extraction and remains queued for source review. Exact-name and exact-submission searches in the checked 2026-09-01 indexes returned no PubMed records and no ClinicalTrials.gov records for K252099; review status is candidate_review_pending. Any candidate literature or registry record remains quarantined as product-family evidence unless exact submission and version linkage is established. Current vendor material is product-family context. Pricing, complete security architecture, contracted deployment, exact reimbursement, and local interoperability remain unverified. Automated exact-name discovery found 0 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision material, vendor product page, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Sources

Source ledger

Sources accessed through 2026-09-04.

Alternatives

Related tools to compare

FDA-cleared K253614

EchoNavigator R5.0

Philips Medical Systems Nederland B.V.

EchoNavigator R5.0 supports an interventionalist or surgeon during cardiovascular treatment by combining live X-ray and live echocardiographic information.

Modality
Fluoroscopy/Angiography
Anatomy
Heart and cardiovascular structures
Decision
2026-03-17
FDA-cleared K252500

CARA System

Cara Medical, Ltd.

CARA assists adult structural-heart and conduction-system procedure planning by segmenting preprocedural CT, visualizing cardiac chambers and conduction landmarks, and overlaying...

Modality
Fluoroscopy/Angiography
Anatomy
Heart/Cardiovascular
Decision
2026-02-20
FDA-cleared K251602

Alphenix, INFX-8000V/B, INFX-8000V/S, V9.6 with aEvolve Imaging

Canon Medical Systems Corporation

Alphenix V9.6 with aEvolve Imaging is a digital radiography and fluoroscopy system for diagnostic and interventional angiography of the labeled vessels, with AI Denoising and MFP...

Modality
Fluoroscopy/Angiography
Anatomy
Heart, brain, abdomen, and lower-extremity vessels
Decision
2025-10-10